
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab's financial outlook is bolstered by the remarkable performance of its leading product, DARZALEX, which recorded worldwide net sales of $3.9 billion in 4Q25, surpassing previous estimates and reflecting strong growth potential. The anticipated increase in DARZALEX royalties to $722 million in 4Q25, alongside the company's robust balance sheet and profitability, further reinforces confidence in its resilience amid broader biotech sector challenges. Additionally, Genmab's expansive pipeline and the presence of various promising clinical data catalysts position the company favorably for continued success in oncology therapeutics.
Bears say
Genmab faces several significant risks that contribute to a negative outlook on its stock, including slowing sales for its leading product, Darzalex, and the potential failure to secure label extensions for it. Additionally, the negative readout from the Phase 3 EPCORE DLBCL-1 trial regarding Epcoritamab has lowered the likelihood of its approval, thereby impacting future revenue streams. Other risks include lower-than-expected market penetration for new products, failures in clinical trials, and broader macroeconomic risks, all of which further strain investor confidence in Genmab's financial stability.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares